[1]
Salehi B, Ata A. V Anil Kumar N, et al Antidiabetic Potential of Medicinal Plants and Their Active Components. Biomolecules 2019; 9: 551.
[2]
Fras Z, Sahebkar A, Banach M. The Use of Aspirin in Contemporary Primary Prevention of Atherosclerotic Cardiovascular Diseases Revisited: The Increasing Need and Call for a Personalized Therapeutic Approach. Am J Cardiovasc Drugs 2020. In press
[3]
Kollia C, Antonopoulos AS, Siasos G, et al. Associations between Adiponectin Gene Variability, Proinflammatory and Angiogenetic Markers: Implications for Microvascular Disease Development in Type 2 Diabetes Mellitus? Curr Vasc Pharmacol 2019; 17: 204-8.
[4]
Gouliopoulos N, Antonopoulos AS, Siasos G, et al. Macrovascular function indices for the prediction of diabetic retinopathy development in patients with type 2 diabetes. Eur J Prev Cardiol 2017; 24: 1405-7.
[6]
Tentolouris A, Eleftheriadou I, Tzeravini E, et al. Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice. Curr Med Chem 2020; 27: 1089-131.
[7]
Antonopoulos AS, Siasos G, Tousoulis D. Microangiopathy, Arterial Stiffness, and Risk Stratification in Patients with Type 2 Diabetes. JAMA Cardiol 2017; 2: 820-1.
[8]
Ambrosini S, Mohammed SA, Lüscher TF, et al. New Mechanisms of Vascular Dysfunction in Cardiometabolic Patients: Focus on Epigenetics. High Blood Press Cardiovasc Prev 2020; 27(5): 363-71.
[9]
Siasos G, Skotsimara G, Oikonomou E, et al. Antithrombotic Treatment in Diabetes Mellitus: A Review of the Literature about Antiplatelet and Anticoagulation Strategies used for Diabetic patients in Primary and Secondary Prevention. Curr Pharm Des 2020; 26(23): 2780-8.
[10]
Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: Epidemiology pathophysiology, and management. JAMA 2002; 287: 2570-81.
[11]
Nilsson J, Bengtsson E, Fredrikson GN, et al. Inflammation and immunity in diabetic vascular complications. Curr Opin Lipidol 2008; 19: 519-24.
[12]
Siasos G, Gouliopoulos N, Moschos MM, et al. Role of endothelial dysfunction and arterial stiffness in the development of diabetic retinopathy. Diabetes Care 2015; 38: e9-e10.
[13]
Batzias K, Antonopoulos AS, Oikonomou E, et al. J Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis. Diabetes Res 2018; 20181232583
[14]
Paschou SA, Siasos G, Bletsa E, et al. The Effect of DPP-4i on Endothelial Function and Arterial Stiffness in Patients with Type 2 Diabetes: A Systematic Review of Randomized Placebo-controlled Trials. Curr Pharm Des 2020; 26(46): 5980-7.
[15]
Althouse AD, Abbott JD, Forker AD, et al. Risk factors for incident peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation in type 2 Diabetes (BARI 2D). Trial Diabetes Care 2014; 37: 1346-52.
[16]
Tousoulis D, Papageorgiou N, Androulakis E, et al. Diabetes mellitus-associated vascular impairment: novel circulating biomarkers and therapeutic approaches. J Am Coll Cardiol 2013; 62: 667-76.
[17]
Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol 2006; 47: 921-9.
[18]
Demarchi A, Somaschini A, Cornara S, Androulakis E. Peripheral Artery Disease in Diabetes Mellitus: Focus on Novel Treatment Options. Curr Pharm Des 2020; 26(46): 5953-68.
[19]
McMurray JJV, Gerstein HC, Holman RR, et al. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2014; 2: 843-51.
[20]
Oikonomou E, Mourouzis K, Fountoulakis P, et al. Interrelationship between diabetes mellitus and heart failure: the role of peroxisome proliferatoractivated receptors in left ventricle performance. Heart Fail Rev 2018; 23: 389-408.
[21]
Tousoulis D, Oikonomou E, Siasos G, et al. Diabetes Mellitus and Heart Failure. Eur Cardiol 2014; 9: 37-42.
[22]
Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41: 255-323.
[23]
Sohrabi C, Saberwal B, Lim WY, et al. Heart Failure in Diabetes Mellitus: An Updated Review. Curr Pharm Des 2020; 26(46): 5933-52.
[25]
Siasos G, Bletsa E, Stampouloglou PK, et al. MicroRNAs in cardiovascular disease. Hellenic J Cardiol 2020; 61: 165-73.
[26]
Briasoulis A, Tousoulis D, Vogiatzi G, et al. MicroRNAs: Biomarkers for cardiovascular disease in patients with diabetes mellitus. Curr Top Med Chem 2013; 13: 1533-9.
[27]
Tentolouris A, Eleftheriadou I, Grigoropoulou P, et al. The association between pulse wave velocity and peripheral neuropathy in patients with type 2 diabetes mellitus. J Diabetes Complications 2017; 31: 1624-9.
[28]
Antonopoulos AS, Siasos G, Konsola T, et al. Arterial wall elastic properties and endothelial dysfunction in the diabetic foot syndrome in patients with type 2 diabetes. Diabetes Care 2015; 38: e180-1.
[29]
Paschou SA, Siasos G, Katsiki N, Tentolouris N, Tousoulis D. The Role of microRNAs in the Development of Type 2 Diabetes Complications. Curr Pharm Des 2020; 26(46): 5969-79.
[30]
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71.
[31]
Siasos G, Stampouloglou PK, Bletsa E, et al. SGLT-2i and Cardiovascular Prognosis. Curr Pharm Des 2020; 26(32): 3905-7.
[32]
Paschou SA, Siasos G. Diabetes and the Heart: New Clinical Trials and Recent Recommendations. Curr Pharm Des 2020; 26(37): 4685-6.
[33]
Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232-42.
[34]
Scirica B, Bhatt D, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with diabetes mellitus. N Engl J Med 2013; 369: 1317-26.
[35]
Marso S, Daniels G, Bron-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 374: 311-22.
[36]
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834-44.
[37]
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-28.